MOVIPREP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169381 | SALIX PHARMS | Colon cleansing compositions and methods |
Sep, 2024
(11 months from now) | |
| US7658914 | SALIX PHARMS | Colon cleansing compositions |
Sep, 2024
(11 months from now) | |
Moviprep is owned by Salix Pharms.
Moviprep contains Ascorbic Acid; Polyethylene Glycol 3350; Potassium Chloride; Sodium Ascorbate; Sodium Chloride; Sodium Sulfate.
Moviprep has a total of 2 drug patents out of which 0 drug patents have expired.
Moviprep was authorised for market use on 02 August, 2006.
Moviprep is available in for solution;oral dosage forms.
The generics of Moviprep are possible to be released after 01 September, 2024.
Market Authorisation Date: 02 August, 2006
Treatment: NA
Dosage: FOR SOLUTION;ORAL
How can I launch a generic of MOVIPREP before it's drug patent expiration?
More Information on Dosage
MOVIPREP family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic